I. Technology Development
Shanghai Hanhong currently possesses a synthetic biology technology platform, a chiral chemistry technology platform, and a green synthesis technology platform. It has a 3,000-square-meter R&D center in Shanghai staffed by 40 researchers, and a 1,000-square-meter R&D laboratory in Lanzhou staffed by 25 researchers. Leveraging these R&D capabilities, the company undertakes technology development projects for chemical products for external clients.
II. Technology Transfer
The CDMO (Contract Development and Manufacturing Organization) business consists of R&D teams, production teams, and service teams.
III. Joint Production
Hanhong Technology possesses strong R&D facilities and has dedicated production and sales teams. Hanhong Technology is willing to engage in extensive collaboration with relevant domestic enterprises in the industrial chain through joint production partnerships, aiming to jointly build an active pharmaceutical ingredient (API) and intermediate supply chain.
IV. Technology Equity Investment
Relying on the company's R&D capabilities and its long-term accumulated project technologies, Shanghai Hanhong is willing to enter into various forms of cooperation through technology equity investment. This approach allows for complementary advantages and aims to jointly expand the industrial chain.
